Tasigna Lawsuit 2026: October Update — Who Qualifies, What the Science Shows & How to File
As of October 2026, people who took Tasigna (nilotinib) for chronic myeloid leukemia and suffered atherosclerosis-related injuries — peripheral arterial occlusive disease, stroke, or heart attack — may be eligible to file a lawsuit alleging Novartis failed to warn about these cardiovascular risks. These are individual lawsuits, deadlines vary by state, and an attorney can evaluate your claim.
Key facts:
- Tasigna (nilotinib) is a Novartis tyrosine kinase inhibitor prescribed for Philadelphia chromosome-positive chronic myeloid leukemia (CML).
- In April 2013, Health Canada reported that Novartis's global safety database held 277 cases of atherosclerosis among Tasigna patients between 2005 and 2013.
- An FDA postmarket review concluded the evidence "strongly suggests an association" between nilotinib and peripheral arterial occlusive disease (PAOD).
- Lawsuits allege Novartis failed to adequately warn U.S. patients and doctors about these cardiovascular risks; compensation varies widely by case.
What Tasigna Is and Why Doctors Prescribe It
Tasigna (nilotinib) is a Novartis medicine for Philadelphia chromosome-positive chronic myeloid leukemia — a slow-growing cancer of the blood and bone marrow. The Philadelphia chromosome is a genetic abnormality carried by most who develop it.
Nilotinib is a tyrosine kinase inhibitor — a targeted therapy that blocks the abnormal protein signal telling leukemia cells to multiply. These drugs transformed CML from a rapidly fatal illness into a manageable chronic condition — which is why Tasigna lawsuits are not about whether the medicine works, but about whether patients were told enough about one of its serious risks.
The Injuries Named in Tasigna Lawsuits
Plaintiffs allege Tasigna caused or accelerated atherosclerosis. Atherosclerosis is the buildup of fatty plaque inside artery walls — narrowing and stiffening them, restricting blood flow so downstream tissue — in the limbs, heart, or brain — is starved of oxygen.
The injuries alleged include peripheral arterial occlusive disease (PAOD), a narrowing of the arteries feeding the limbs; heart attacks rooted in coronary artery disease; and ischemic strokes from blocked blood flow to the brain — severe enough in some cases to require emergency surgery, cause lasting disability, or prove fatal.
What the Science Shows
Concerns accumulated over more than a decade of published research. A 2011 study reported vascular problems in roughly one in four Tasigna-treated patients, with about 16 percent developing peripheral arterial disease; further studies from the United States, Canada, and Europe built a consistent picture.
In April 2013, Health Canada reported 277 cases of atherosclerosis among Tasigna patients in Novartis's global safety database from 2005 to 2013, and new safety information was added to the Canadian product monograph. A U.S. Food and Drug Administration postmarket review concluded the findings "strongly suggest an association" between nilotinib and peripheral arterial occlusive disease.
The Failure-to-Warn Allegation at the Center of These Cases
Every Tasigna lawsuit turns on one question: did Novartis adequately warn patients and doctors about the cardiovascular risk? Plaintiffs allege the company knew — or should have known — about the atherosclerosis signal before U.S. patients received meaningful notice, pointing to the 2013 Canadian action as proof a clearer warning was possible, and that Tasigna was marketed as a superior CML therapy while the vascular risk stayed in the shadows.
Novartis has not conceded these allegations; each case will be decided on its own facts. Still, failure-to-warn claims sit at the heart of many pharmaceutical mass torts — including ongoing Depo-Provera litigation, where plaintiffs similarly argue the label lagged behind emerging risk signals.
Who May Qualify to File a Claim
No attorney can promise a case before reviewing records, but those typically evaluated share a common profile: prescribed Tasigna for CML, then later diagnosed with atherosclerosis, peripheral arterial occlusive disease, a heart attack, a stroke, or another cardiovascular injury that followed treatment. Where the patient has died, surviving family members may be able to file on their behalf.
Timing and documentation matter enormously: pharmacy records must establish you took the drug, and medical records must connect the diagnosis to the treatment period. A qualified mass tort attorney reviews these records — usually at no charge — before advising whether your facts support a claim.
Where the Litigation Stands in October 2026
Tasigna lawsuits have been filed in U.S. courts, and attorneys continue to review and file new cases. Unlike a class action, each case stands on its own facts — your injury, your treatment history, your damages. As with other active mass torts — for example, Suboxone tooth-decay litigation — there is no guaranteed outcome and no published timetable.
One date matters: the filing deadline. Statutes of limitations vary by state, and in drug-injury cases the clock often starts when you discovered — or should have discovered — the drug-injury connection. Because that analysis is fact-specific, waiting is the one mistake that cannot be undone.
How to File a Tasigna Lawsuit
Filing begins with evidence, not paperwork: your prescription history — pharmacy records showing when you took Tasigna — and your cardiovascular medical records, including the diagnosis of atherosclerosis, PAOD, heart attack, or stroke. If records are scattered across providers, an attorney's office can usually help assemble them.
Next, speak with a qualified pharmaceutical injury attorney. Most offer a free case evaluation and take these cases on contingency — you pay nothing up front, and the attorney receives a percentage, typically 33 to 40 percent, only if your case recovers compensation. For example, if a case settles for $300,000 with a 33% fee, the fee is $99,000 (before case expenses, deducted separately). Court filing fees are typically a few hundred dollars.
For plain-language explainers of how mass tort cases move through the courts, watch our explainer videos on our YouTube channel. One firm boundary: this article is general educational information, not legal advice; consult a qualified attorney about your situation.
Who Benefits From This — and Who Does Not
As of October 2026, people who took Tasigna (nilotinib) for chronic myeloid leukemia and suffered atherosclerosis-related injuries may be eligible to file a lawsuit. This article helps some readers — not all.
Who benefits:
- People who took Tasigna for CML and were later diagnosed with a cardiovascular injury. Gather your treatment and diagnosis records and ask a qualified attorney to evaluate your claim — no outcome is guaranteed.
- Families of a patient diagnosed with PAOD, stroke, or heart attack after Tasigna. Check treatment and diagnosis dates, since deadlines vary by state.
- Readers who want to understand what the science shows. Read the section on the 277 Health Canada cases and the FDA postmarket review before taking any step.
Who does not benefit:
- People who never took Tasigna. The lawsuits require treatment with nilotinib for Philadelphia chromosome-positive chronic myeloid leukemia.
- People with no diagnosed atherosclerosis-related injury. The lawsuits target specific injuries: peripheral arterial occlusive disease, stroke, heart attack, or a related cardiovascular injury.
- Anyone seeking a guaranteed payout. Compensation varies widely by case, most settlements are confidential, and no outcome is guaranteed.
Related reading: Paraquat after Durnell: will 6,000 Parkinson's cases survive?.
Frequently Asked Questions
Do I qualify for a Tasigna lawsuit?
You may qualify if you took Tasigna for CML and were later diagnosed with atherosclerosis, peripheral arterial occlusive disease, a heart attack, a stroke, or a related cardiovascular injury. A qualified attorney reviews your records to evaluate the claim — no outcome is guaranteed.
What is the deadline to file a Tasigna claim?
Deadlines vary by state, and the clock often starts when you discovered — or reasonably should have discovered — the link between Tasigna and your injury. Because this analysis is highly fact-specific, speak with an attorney promptly rather than assuming you have time.
How much does it cost to file?
Most pharmaceutical injury attorneys offer free evaluations and work on contingency — typically 33 to 40 percent of any recovery, with no upfront payment, and court filing fees are usually a few hundred dollars. For example, if a case settles for $300,000 with a 33% fee, the fee is $99,000 before separately deducted case expenses.
How much compensation could I receive?
Compensation varies widely by case. No reliable public per-case figures exist because most settlements are confidential. Your compensation depends on your specific facts, including injury severity, liability, and jurisdiction.
Has Tasigna been recalled?
No. Tasigna remains available with cardiovascular warnings on its label; the lawsuits allege those warnings were inadequate or came too late.
Who cannot file a Tasigna lawsuit?
People who never took Tasigna, people with no diagnosed atherosclerosis-related injury, and anyone seeking a guaranteed payout — compensation varies widely by case, most settlements are confidential, and no outcome is guaranteed.